Join to View Full Profile
264 North Highland Springs AvenueBanning, CA 92220
Phone+1 801-580-2232
Dr. Kirstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I retired from family medicine 7/31/13 and am working part time at Velocity Clinical Research San Bernardino, California. Velocity is a stand alone clinical research facility where we do a wide variety of research studies on chronic conditions, such as gout, HTN, DM, hyperlipidemia, obesity, as well as new vaccines.
Education & Training
University of Utah HealthResidency, Family Medicine, 1978 - 1981
David Geffen School of Medicine at UCLAClass of 1978
Certifications & Licensure
CA State Medical License 2018 - 2026
American Board of Family Medicine Family Medicine
Clinical Trials
- Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia Start of enrollment: 2009 Jun 01
- The Plecanatide Chronic Idiopathic Constipation (CIC) Study Start of enrollment: 2011 Oct 01
- Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.Roger A Fielding, Michael M Dao, Kevin Cannon, Moise Desvarieux, Sam S Miller
Journal of Cachexia, Sarcopenia and Muscle. 2025-04-01 - 1 citationsSafety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in ...Sylvie Pichon, Annick Moureau, Celine Petit, Judith L Kirstein, Eric Sheldon
Vaccine. 2024-04-11 - 89 citationsEvaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.C Buddy Creech, Evan Anderson, Vladimir Berthaud, Inci Yildirim, Andrew M Atz
The New England Journal of Medicine. 2022-05-26
Press Mentions
Moderna Phase 3 Trial Data Shows 94 Percent Efficacy Against COVID-19December 4th, 2020
Une Nouvelle Étude De Phase III Montre Une Efficacité Significativement plus Grande Chez Les Enfants De 6 Mois À 24 Mois Qui Reçoivent Un Vaccin Avec Adjuvant Contre La Grippe (aQIV)September 12th, 2017- New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (aQIV)September 11th, 2017
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
